Cancer risk with topical pimecrolimus and tacrolimus.
- Published Article
- Publication Date
Dec 01, 2005
(1) Disturbing reports of cancers linked to topical application of tacrolimus or pimecrolimus have been published. Some involved children. Animal studies had already shown a dose-dependent increase in the incidence of lymphoma in mice and monkeys. (2) In practice, it is better to avoid topical application of these immunosuppressants, which have a negative risk-benefit balance.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/03/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/16400745